A team of researchers led by Worcester Polytechnic Institute (WPI), USA, Provost Wole Soboyejo has identified targeted drugs that reduced the sizes of hard-to-treat breast cancer tumours in mice without inducing the toxic side effects that are typically associated with conventional chemotherapy.
The researchers said in an article published in Scientific Reports that a molecular recognition unit attached to drugs specifically targeted “triple-negative” breast cancer tumours, which typically do not respond to targeted therapies.
The targeted drugs eliminated or reduced the sizes of breast cancer tumours in laboratory experiments that were performed on mice.
No toxic side effects were observed in the experiments.
“When injected into the bloodstream, only a small fraction of traditional chemotherapeutic drugs reaches tumours,” Soboyejo said. “It usually takes relatively high concentrations of conventional cancer drugs to have therapeutic effects on tumours. Hence, such concentrations are often toxic to other cells. In our case, the targeting drugs were more effective at shrinking and eliminating triple-negative breast tumours in mice. They also eliminated tumours without inducing toxicity.”
Breast cancer is the most commonly diagnosed cancer in women.
Chemotherapy kills fast-growing tumour cells by flooding a patient’s body with potent drugs, but the treatment often produces toxic side effects.
Targeted therapy aims to reduce side effects by delivering chemotherapeutic drugs directly to breast cancer tumour cells.
The drugs seek out and bind to specific cellular structures known as receptors.
Three common receptors that are over-expressed on the surfaces of breast cancer tumour cells are HER2, a growth factor, as well as oestrogen and progesterone hormones.
Most breast cancer treatments target HER2 receptors.
However, between 10% and 17% of all breast cancers lack HER2, oestrogen, and progesterone receptors.
These “triple-negative” breast cancers are more prevalent in younger women, African American women, and African women.
Soboyejo, inspired by a relative’s battle with breast cancer, previously studied luteinising hormone-releasing hormone (LHRH) as a targeting mechanism to deliver magnetic nanoparticles to breast tumours.
The targeted magnetic nanoparticles were found to improve the imaging of breast tumours in nude mice, a type of laboratory mouse.
LHRH is a naturally occurring hormone in mammals.
It is essential for reproduction.
More recently, Soboyejo began studying LHRH as a targeting mechanism for chemotherapeutic drugs.
His work has been funded by WPI and the Pan African Materials Institute at the African University of Science and Technology (AUST) in Abuja, Nigeria, which is funded by the World Bank.
In this study, the researchers attached the chemotherapy drug paclitaxel to LHRH.
They also attached prodigiosin, a natural substance with anti-cancer properties, to LHRH.
Both combination molecules were tested against triple-negative breast cancer cells and tissues.
Soboyejo’s team hopes to continue work on LHRH-targeted nanoparticles and therapeutic drugs, and to position them for human clinical trials on breast cancer patients.
The group is also working to identify other targeted drugs and nanoparticles for the detection and treatment of other tumours.
“The fact that we could target triple-negative breast cancer in mice models is important. However, I think this method has major implications for targeted cancer treatment in general,” Soboyejo said.
Source: Worcester Polytechnic Institute